Gary Middleton - Concepedia

Author

Gary Middleton

Also Known As

Amir Montazeri, Bernard Olisemeke, Elspeth Insch, Eustace Fontaine, G Middleton, G W MIDDLETON, G W Middleton, G. MIDDLETON, G. Middleton, G. W. MIDDLETON

458

Publications

29.2K

Citations

H-Index

Concepts

All Affiliations

University of Birmingham University College London Royal Marsden Hospital The Christie NHS Foundation Trust Cancer Research UK

About

Gary Middleton is an author at University of Birmingham specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	64	7.6K
2	Health Sciences	14	15	992
3	Engineering	3	3	586
4	Public Health	3	3	1.8K
5	Humanities	1	1	21

Gary Middleton

144

Publications

25.4K

Citations

H-Index

Page 1

	Year	Citations
Tracking the Evolution of Non–Small-Cell Lung Cancer Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan, New England Journal of Medicine	2017	2.3K
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer David Cunningham, Naureen Starling, Sheela Rao, New England Journal of Medicine	2008	2.3K
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh, The Lancet	2017	1.9K
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Christopher Abbosh, Nicolai J. Birkbak, Gareth A. Wilson, Nature	2017	1.8K
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Cell	2017	1.3K
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Vasileios Angelis, The Lancet Covid-19 MortalityEpidemiologyCancer EpidemiologyMedicineCancer Management	2020	1.1K
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, Journal of Clinical Oncology	2008	945
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Ian Chau, David Cunningham, David González, The Lancet Oncology OncologyOpen-label Phase 3Cancer ManagementPathologyCancer Treatment	2013	723
Lung adenocarcinoma promotion by air pollutants William Hill, Emilia L. Lim, Clare E. Weeden, Nature AsthmaLung DepositionEnvironmental Lung DiseasesLung InflammationRespiratory Toxicology	2023	663
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, The Lancet Oncology Primary Tumour SubtypeEpidemiologyCancer EpidemiologyCovid-19 PrevalenceMedicine	2020	599

Page 1